DDInter596 DDInter1094
Doxorubicin is a cytotoxic anthracycline antibiotic isolated from cultures of Streptomyces peucetius var. caesius along side with daunorubicin, another cytotoxic agent, in 1970.[A1575,A257709,A257614] Although they both have aglyconic and sugar moieties, doxorubicin's side chain terminates with a primary alcohol group compared to the methyl group of daunorubicin. Although its detailed molecular mechanisms have yet to be understood, doxorubicin is generally thought to exert its effect through DNA intercalation, which eventually leads to DNA damage and the generation of reactive oxygen species. Thanks to its efficacy and broad effect, doxorubicin was approved by the FDA in 1974 to treat a variety of cancer, including but not limited to breast, lung, gastric, ovarian, thyroid, non-Hodgkin’s and Hodgkin’s lymphoma, multiple myel
Lorlatinib is a third-generation ALK tyrosine kinase inhibitor (TKI) for patients with ALK-positive metastatic non-small cell lung cancer which was first approved by the US FDA in November of 2018. It was subsequently approved by the EMA in 2019 for the treatment of select patients with previously treated advanced ALK-positive non-small cell lung cancer, followed by an expanded approval in 2022 to include lorlatinib as a first-line treatment option in advanced ALK-positive NSCLC.
Doxorubicin {u} (Compound) binds {v} (Gene) ABCB1
ABCB1 {u} (Gene) is bound by {v} (Compound) Lidocaine
Lidocaine {u} may cause a minor interaction that can limit clinical effects when taken with {v} Lorlatinib
Doxorubicin {u} (Compound) binds {v} (Gene) ABCB1
ABCB1 {u} (Gene) is bound by {v} (Compound) Rilpivirine
Rilpivirine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Lorlatinib
Doxorubicin {u} (Compound) causes {v} (Side Effect) Nausea
Nausea {u} (Side Effect) is caused by {v} (Compound) Lidocaine
Lidocaine {u} may cause a minor interaction that can limit clinical effects when taken with {v} Lorlatinib
Doxorubicin {u} (Compound) causes {v} (Side Effect) Urticaria
Urticaria {u} (Side Effect) is caused by {v} (Compound) Triamcinolone
Triamcinolone {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Lorlatinib
Doxorubicin {u} (Compound) causes {v} (Side Effect) Local reaction
Local reaction {u} (Side Effect) is caused by {v} (Compound) Nafcillin
Nafcillin {u} may lead to a major life threatening interaction when taken with {v} Lorlatinib
Doxorubicin {u} (Compound) binds {v} (Gene) CYP2B6
CYP2B6 {u} (Gene) is bound by {v} (Compound) Dexamethasone
Dexamethasone {u} may lead to a major life threatening interaction when taken with {v} Lorlatinib
Doxorubicin {u} (Compound) resembles {v} (Compound) Daunorubicin
Daunorubicin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Fostemsavir
Fostemsavir {u} may cause a minor interaction that can limit clinical effects when taken with {v} Lorlatinib
Doxorubicin {u} (Compound) resembles {v} (Compound) Daunorubicin
Daunorubicin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Rilpivirine
Rilpivirine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Lorlatinib
Doxorubicin {u} (Compound) resembles {v} (Compound) Epirubicin
Epirubicin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Bexarotene
Bexarotene {u} may cause a minor interaction that can limit clinical effects when taken with {v} Lorlatinib
Doxorubicin {u} (Compound) resembles {v} (Compound) Daunorubicin
Daunorubicin {u} may lead to a major life threatening interaction when taken with {v} Tofacitinib
Tofacitinib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Lorlatinib
Doxorubicin (Compound) binds ABCB1 (Gene) and ABCB1 (Gene) is bound by Lidocaine (Compound) and Lidocaine may cause a minor interaction that can limit clinical effects when taken with Lorlatinib
Doxorubicin (Compound) binds ABCB1 (Gene) and ABCB1 (Gene) is bound by Rilpivirine (Compound) and Rilpivirine may cause a moderate interaction that could exacerbate diseases when taken with Lorlatinib
Doxorubicin (Compound) causes Nausea (Side Effect) and Nausea (Side Effect) is caused by Lidocaine (Compound) and Lidocaine may cause a minor interaction that can limit clinical effects when taken with Lorlatinib
Doxorubicin (Compound) causes Urticaria (Side Effect) and Urticaria (Side Effect) is caused by Triamcinolone (Compound) and Triamcinolone may cause a moderate interaction that could exacerbate diseases when taken with Lorlatinib
Doxorubicin (Compound) causes Local reaction (Side Effect) and Local reaction (Side Effect) is caused by Nafcillin (Compound) and Nafcillin may lead to a major life threatening interaction when taken with Lorlatinib
Doxorubicin (Compound) binds CYP2B6 (Gene) and CYP2B6 (Gene) is bound by Dexamethasone (Compound) and Dexamethasone may lead to a major life threatening interaction when taken with Lorlatinib
Doxorubicin (Compound) resembles Daunorubicin (Compound) and Daunorubicin may cause a moderate interaction that could exacerbate diseases when taken with Fostemsavir and Fostemsavir may cause a minor interaction that can limit clinical effects when taken with Lorlatinib
Doxorubicin (Compound) resembles Daunorubicin (Compound) and Daunorubicin may cause a moderate interaction that could exacerbate diseases when taken with Rilpivirine and Rilpivirine may cause a moderate interaction that could exacerbate diseases when taken with Lorlatinib
Doxorubicin (Compound) resembles Epirubicin (Compound) and Epirubicin may cause a moderate interaction that could exacerbate diseases when taken with Bexarotene and Bexarotene may cause a minor interaction that can limit clinical effects when taken with Lorlatinib
Doxorubicin (Compound) resembles Daunorubicin (Compound) and Daunorubicin may lead to a major life threatening interaction when taken with Tofacitinib and Tofacitinib may cause a moderate interaction that could exacerbate diseases when taken with Lorlatinib